关节置换术后抗凝药物预防深静脉血栓及相关并发症的临床研究进展

发布时间：2018-01-18 14:38

本文关键词：关节置换术后抗凝药物预防深静脉血栓及相关并发症的临床研究进展　出处：《现代生物医学进展》2016年12期 　论文类型：期刊论文

【摘要】：抗凝药物有助于预防全髋关节置换术和全膝关节置换术后深静脉血栓形成,临床上最常使用的传统抗凝药物如低分子肝素、华法林等可以起到很好的预防效果。目前有一类新的口服抗凝药物已经用于临床,为关节置换术后患者带来了一种更方便、安全和有效预防血栓的治疗选择。本篇综述主要针对传统抗凝药物低分子肝素及维生素K拮抗剂,直接凝血酶抑制剂达比加群,以及选择性Xa因子抑制剂利伐沙班和阿哌沙班,对迄今为止传统抗凝药物在全髋关节置换术和全膝关节置换术患者中的临床使用经验、优缺点、以及新型口服抗凝药物最新临床用药进展进行综述,为关节置换术后患者预防深静脉血栓提供用药参考。
[Abstract]:Anticoagulants help prevent deep vein thrombosis after total hip arthroplasty and total knee arthroplasty. Traditional anticoagulants such as low-molecular-weight heparin are most commonly used clinically. Warfarin and so on can play a very good preventive effect. At present, there is a new class of oral anticoagulants that have been used in clinical practice, which has brought a more convenient for patients after joint replacement. This review focuses on the traditional anticoagulant low molecular weight heparin and vitamin K antagonists, direct thrombin inhibitor Darbiquar. The clinical experience of traditional anticoagulants in total hip arthroplasty and total knee arthroplasty is also discussed, as well as the clinical experience, advantages and disadvantages of the selective Xa factor inhibitors rivashaban and piperazabine in patients undergoing total hip arthroplasty and total knee arthroplasty. The new oral anticoagulant is reviewed in order to provide a reference for the prevention of deep venous thrombosis after arthroplasty.
【作者单位】：南方医科大学南方医院关节与骨病外科;
【基金】：国家自然科学基金项目(81501904) 广东省自然科学基金项目(2014A030310241)
【分类号】：R687.4
【正文快照】： Chinese Library Classification(CLC):R687.4 Document code:AArticle ID:1673-6273(2016)12-2376-04前言全髋关节置换术(Total Hip Arthroplasty,THA)和全膝关节置换术(Total Knee Arthroplasty,TKA)是当今最常见的骨科手术。尽管全髋关节置换术和全膝关节置换术可以显著改

【相似文献】